Newron Pharmaceuticals SpAXSWX:NWRN +1.44%62 Median PS Value is CHF11.77 as of Jun. 27, 2026, which is 100% below its 10-year median of 0.43. GuruFocus rates XSWX:NWRN with a GF Score™ of 62/100 and a GF Value™ of CHF12.92 (Fairly Valued). The stock has 5 warning signs investors should review. Among 276 Biotechnology companies, Newron Pharmaceuticals SpA ranks worse than 77.17% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Newron Pharmaceuticals SpA's Median PS Value or its related term are showing as below:
XSWX:NWRN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23 Med: 0.43 Max: 2.03
Current: 1.07
During the past 13 years, the highest Price to Median PS Value of Newron Pharmaceuticals SpA was 2.03. The lowest was 0.23. And the median was 0.43.
XSWX:NWRN's Price-to-Median-PS-Value is ranked worse than 77.17% of 276
companies
in the Biotechnology industry
Industry Median: 0.62
vs XSWX:NWRN: 1.07
Newron Pharmaceuticals SpA (XSWX:NWRN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Newron Pharmaceuticals SpA's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
12.64
/
11.77
=
1.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA Median PS Value Related Terms
Newron Pharmaceuticals SpA Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NWRN vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 13.1215.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.897.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Median PS Value of CHF11.77 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Newron Pharmaceuticals SpA and its competitors. This is 2637% above median its historical median of 0.43. Over the past decade, Newron Pharmaceuticals SpA's Median PS Value has ranged from 0.23 to 2.03. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #213 out of 276 companies in the Biotechnology industry, placing it in the top 77.2%.
Is Newron Pharmaceuticals SpA's Median PS Value too high?
Newron Pharmaceuticals SpA's current Median PS Value of CHF11.77 is 2637% above median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 2.03. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #213 out of 276 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #213 out of 276 companies for Median PS Value. This places Newron Pharmaceuticals SpA in the lower half of its industry. The industry median Median PS Value is 0.62. Historically, Newron Pharmaceuticals SpA's own Median PS Value has ranged from 0.23 to 2.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Newron Pharmaceuticals SpA and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current Median PS Value is CHF11.77, which is 2637% above median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Fairly Valued. The stock's GF Value™ is CHF12.92, compared to a current price of CHF12.64 — trading 2.2% below its estimated fair value. The current Median PS Value is CHF11.77, which is 2637% above median its 10-year median of 0.43. Newron Pharmaceuticals SpA's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Median PS Value is CHF11.77 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of CHF12.64 is trading 2.2% below its estimated GF Value™ of CHF12.92.
GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.
Key valuation signals for XSWX:NWRN:
Median PS Value: CHF11.77 (2637% above median its 10-year median of 0.43)
GF Value™: CHF12.92 vs. price of CHF12.64 (2.2% below fair value)
No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
62GF Score
Get the complete analysis for XSWX:NWRN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NWRN has been successfully added to your 
